AveXis — Investor Presentation (January 2017)
21 slides from AveXis's investor presentation, Jan 9, 2017
Slide 1: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains forward-looking statements, including statements about: the timing, progress and results of preclinical studies and clinical trials for AVXS-101, including statements regarding the timing of initiation and completion of studies or trials and re
Slide 2: Our Strategy
Our Strategy 3 Build pipeline of gene therapy treatments beyond SMA Expand development of AVXS-101 into SMA Type 2 Establish foundational presence in SMA Type 1 Vision: Leader in rare and life-threatening neurological genetic diseases Strategic Focus & Investment Time
Slide 3: Overview of SMA
Overview of SMA 4 SMA is a devastating orphan disease that results in motor neuron loss and progressive weakness; it is the most common genetic cause of infant death Incidence: ~1 in 10,000 live births Caused by reduced SMN (survival motor neuron) protein levels from loss of/defective SMN1 gene SMA
Slide 4: SMA Types: A Devastating Disease
SMA Types: A Devastating Disease 5 TYPE 1 TYPE 2 TYPE 3 TYPE 4 SMN2 Copy Number Two Three or Four Three or Four Four to Eight Onset Before 6 Months 6-18 Months Early childhood to early adulthood (juvenile) Adulthood (20s-30s) usually after 30 Incidence per Live Birth Approximately 60% Approximately
Slide 5: SMA Market Opportunity
SMA Market Opportunity 6 The SMA patient population is well-defined in the U.S. and has similar incidence rates in Europe 1 in 50 (~6 million Americans) are genetic carriers ~10,000 SMA patients in the U.S. All SMA has same root cause – deletion or point mutation of SMN1 gene SMA in the U.S. Inciden
Slide 6: AVXS-101 Targets the Primary SMN Gene
AVXS-101 Targets the Primary SMN Gene 7 NORMAL INDIVIDUAL SMA-AFFLICTED INDIVIDUAL SMA-AFFLICTED INDIVIDUAL TREATED WITH AVXS-101 SMN Genes SMN Protein SMN1 Primary SMN2 Back up SMN Genes SMN Protein SMN1 SMN2 Back up SMN Genes SMN Protein SMN1 SMN2 Back up AVXS-101 Primary Functional SMN Protein No
Slide 7: Our Solution: AVXS-101 An Innovative Treatment Approach for SMA
Our Solution: AVXS-101 An Innovative Treatment Approach for SMA 8 scAAV ITR Continuous Promoter Human SMN Transgene scAAV ITR KEY COMPONENTS PURPOSE Recombinant AAV9 Capsid Shell Ability to deliver across the blood brain barrier (BBB) and into the spinal cord - Avoids the need for intrathecal delive
Slide 8: Natural History of SMA Type 1
Natural History of SMA Type 1 “floppy baby” syndrome muscle weakness (legs more than arms) poor head control belly breathing bulbar muscle weakness (weak cry, difficulty swallowing, aspiration) will never sit unsupported loss of motor function: NeuroNEXT -- CHOP INTEND decrease of 10.5 points/yr. PN
Slide 9: Children with SMA Type 1 Do Not Reach Any Major Motor Milestones
Children with SMA Type 1 Do Not Reach Any Major Motor Milestones Retrospective Study from large multi-center datasets (US and EU) Patients (n=33) have genetically confirmed homozygous deletion of exon 7 in SMN1 gene; categorized according to Dubowitz’s decimal classification (confirmation of SMN1 st
Slide 10: Phase 1 Trial Design: Trial Overview
Phase 1 Trial Design: SMA Type 1 11 TRIAL OVERVIEW Route of Administration One-time intravenous infusion through peripheral limb vein Prednisolone 1 mg/kg 1 day Pre-GT Trial Design Open-label, dose-escalation Principal Investigator Jerry R. Mendell, M.D. TRIAL OVERVIEW Study Site OBJECTIVES Primary
Slide 11: Event-Free Survival Data
* A month is defined as 30 days Cohort 1 6.7E13 vg/kg Cohort 2 2.0E14 vg/kg PNCR (Finkel) 2014 Natural History Study: 75% event-free 50% event-free 25% event-free 8% event-free 12 SURVIVAL DATA 9/9 reached 20 mo. event-free (8% PNCR) 12/12 reached 13.6 mo. event-free (25% PNCR) 15/15 reached 10.5 mo
Slide 12: CHOP INTEND vs. Age – September 15, 2016
CHOP INTEND vs. Age – September 15, 2016 Early intervention and dose appear to affect response 6 13 COHORT 1 (n=3) Baseline Age (months): 5.9 [median], 6.3 [mean] Current Age* (months): 30.8 [median], 30.3 [mean] Mean CHOP INTEND Increase: 9.0 points COHORT 2 (n=12) Baseline Age (months): 3.1 [media
Slide 13: Safety Data – September 15, 2016
Safety Data – September 15, 2016 SAFETY AND TOLERABILITY OBSERVATIONS No new treatment-related SAEs or AEs observed As previously reported, a total of 5 treatment-related AEs in 4 patients have been observed to date Treatment-related SAEs and AEs were clinically asymptomatic elevated liver function
Slide 14: Motor Milestone Achievement in Proposed Therapeutic Dose (Interim Data)
Motor Milestone Achievement in Proposed Therapeutic Dose (Interim Data) 16 Cohort 2 2.0e14 vg/kg Age at GT (mos) Motor Milestone Achievement Brings hand to mouth Head control Rolls over (partial) Rolls over (complete) Sitting with assistance Sitting unassisted E.04 6 E.05 4 E.06 2 E.07 4 E.08 8 E.09
Slide 15: AVXS-101 Pivotal Trial in SMA Type 1: Update Based on FDA Type B Meeting
AVXS-101 Pivotal Trial in SMA Type 1 Update Based on Ongoing Dialogue and FDA Type B Meeting Minutes Held 9/30/16 17 Study Overview To reflect single-arm design with a natural history comparator Expected to enroll approximately 20 patients Endpoints to include safety, achievement of motor milestones
Slide 16: SMA Type 2 Strategy
SMA Type 2 Strategy Potentially streamlines development of Type 2 clinical data set Eliminates the need for a comparability analysis later in development Simplifies the development pathway by using one, consistent product; FDA in general prefers use of a consistent product process in program develop
Slide 17: Company Milestones
Company Milestones 19 Type 1 Program Type 2 Program 2016 2017 Manufacturing Q4 2017: Initiate quarterly updates on ongoing pivotal trial 1H 2017: Initiate SMA Type 1 pivotal trial in U.S.* Q1 2017: Anticipated CMC Type B meeting with FDA Q1 2017: Provide update on EU regulatory pathway and trial des
Slide 18: Manufacturing Strategy
Manufacturing Strategy 20 Executing a “Parallel Path” Approach (CMO and AveXis Build) to Enable both Clinical Trial and Commercial Long-term Sustainable Supply Manufacturing Overview Contract Manufacturing Organizations (CMOs) Continue to utilize Contract Manufacturing Organizations (CMOs) and Third
Slide 19: Key Investment Highlights
Key Investment Highlights 21 21 AVXS-101 is a gene therapy for SMA Type 1 with clinical POC 15 patients dosed in two distinct dosing cohorts; appears to be generally well tolerated Early and sustained motor function improvements above baseline Two-thirds of patients in proposed therapeutic dose coho
Slide 20: Key Investment Highlights
Key Investment Highlights 15 patients dosed in two distinct dosing cohorts; appears to be generally well tolerated AVXS-101 is a. gene Early and sustained motor function improvements above baseline De SASSER - Two-thirds of patients in proposed therapeutic dose cohort able to sit unassisted with cli
Slide 21: Thank You
Thank You avelis